NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03306264,"Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML",https://clinicaltrials.gov/study/NCT03306264,,COMPLETED,"Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m\^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, participants continued to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the participants discontinued treatment or withdrew from the study.",YES,Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia,DRUG: ASTX727|DRUG: Dacogen,"Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine, Total 5-day ASTX727 AUC0-24 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-24 (first ASTX727 dose) was added to (Day 2 AUC0-24+ Day 5 AUC0-24) × 2. Decitabine 5-day AUC0-24 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-24+ Day 5 AUC0-24) / 2 was multiplied by 5. If AUC0-24 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-24 on Day 5; the converse was also true., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)","MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs), An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first., From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)|AML: Number of Participants With Treatment-emergent Adverse Events (AEs), An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first., From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)|MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs, TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal., From randomization up to 30 days after last dose of study treatment (up to approximately 2.7 years)|AML: Number of Participants With Grade 3 or Higher TEAEs, TEAEs were defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a post-treatment alternative anti-cancer treatment, whichever occurred first. Severity of AEs were graded using CTCAE version 4.03. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal., From randomization up to 30 days after last dose of study treatment (up to approximately 2.4 years)|Maximum Percentage of Long Interspersed Nucleotide Elements (LINE)-1 Demethylation, Summarized data for Cycle 1 and Cycle 2 was reported., Pre-dose on Day 1 of Cycles 1 and 2 (as Baseline), and Days 8, 15 and 22 of Cycles 1 and 2 (each cycle= 28 days)|Total 5-day Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine, Total 5-day ASTX727 AUC0-inf exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-inf (first ASTX727 dose) was added to (Day 2 AUC0-inf+ Day 5 AUC0-inf) × 2. Decitabine 5-day AUC0-inf exposures after IV decitabine were calculated as follows: (Day 1 AUC0-inf+ Day 5 AUC0-inf) / 2 was multiplied by 5. If AUC0-inf on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-inf on Day 5; the converse was also true., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)|Total 5-day Area Under the Curve From 0 to Last Quantifiable Concentration (AUC0-last) After Treatment With ASTX727 And IV Decitabine, Total 5-day ASTX727 AUC0-last exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-last (first ASTX727 dose) was added to (Day 2 AUC0-last + Day 5 AUC0-last) × 2. Decitabine 5-day AUC0-last exposures after IV decitabine were calculated as follows: (Day 1 AUC0-last + Day 5 AUC0-last) / 2 was multiplied by 5. If AUC0-last on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-last on Day 5; the converse was also true., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)|Total 5-day Area Under the Curve From 0 to 8 Hours (AUC0-8) After Treatment With ASTX727 And IV Decitabine, Total 5-day ASTX727 AUC0-8 exposures were calculated using PK data from 3 days of serial PK sampling, Day 1 AUC0-8 (first ASTX727 dose) was added to (Day 2 AUC0-8 + Day 5 AUC0-8) × 2. Decitabine 5-day AUC0-8 exposures after IV decitabine were calculated as follows: (Day 1 AUC0-8 + Day 5 AUC0-8) / 2 was multiplied by 5. If AUC0-8 on Day 2 (for ASTX727) or Day 1 (IV decitabine) was not available, it was replaced by AUC0-8 on Day 5; the converse was also true., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 to 5 of Cycle 1 and 2 (each cycle= 28 days)|Area Under the Curve From 0 to Infinity (AUC0-inf) After Treatment With ASTX727 And IV Decitabine, AUC0-inf was calculated using the formula AUClast + (Clast / λZ), where Clast is the last quantifiable concentration and λZ is the elimination rate constant. AUC0-inf will be calculated using the linear up-log down method. Summarized data has been reported for cycle 1 and 2., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)|Maximum Observed Plasma Concentration (Cmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer, Summarized data of Cmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Cmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)|Time to Reach Maximum Plasma Concentration (Tmax) of Decitabine, Cedazuridine, and Cedazuridine-epimer, Summarized data of Tmax on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of Tmax on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)|Apparent Oral Clearance (CL/F) of Oral Decitabine and Cedazuridine, Oral CL/F for oral decitabine was measured only on Day 1 and oral CL/F for oral cedazuridine was measured on Days 1, 2 and 5. Summarized data of Oral CL/F for oral decitabine on Day 1 for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of oral CL/F for oral cedazuridine on Day 1,2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727., Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)|Apparent Elimination Half Life (t1/2) of Decitabine, Cedazuridine, and Cedazuridine-epimer, Summarized data of t1/2 on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727. Similarly, summarized data of t1/2 on Day 1 and 5 respectively for Cycle 1 and 2 has been reported for IV Decitabine., ASTX727: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2; Decitabine: Pre-dose, 0.25, 0.5, 1, 1.08, 1.5, 2, 3, 4, 6, 8 hours post-dose on Days 1 and 5 of Cycle 1 and 2 (each cycle= 28 days)|Apparent Volume of Distribution (Vz/F) of Oral Decitabine and Cedazuridine, Summarized data of Vz/F on Day 1, 2 and 5 respectively for Cycle 1 and 2 has been reported for ASTX727., Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose on Days 1, 2 and 5 of Cycle 1 and 2 (each cycle= 28 days)|MDS/CMML: Percentage of Participants With Complete Response (CR), Marrow CR (mCR), Partial Response (PR), Hematologic Improvement (HI) Based on International Working Group (IWG) 2006 Myelodysplastic Syndromes (MDS) Response Criteria, CR: normal peripheral, persistent granulocyte count ≥1.0x10\^9/liter(L), platelet ≥100x10\^9/L, Hemoglobin (Hgb) ≥11g/dL, normal bone marrow with persistent marrow blasts ≤5%. mCR: reduction of bone marrow blasts to≤5%, decrease by 50% or more with/without normalization of peripheral counts.PR: normal peripheral counts, granulocyte count ≥1.0x10\^9/L, platelet count ≥100x10\^9/L, Hgb ≥11 g/dL, normal bone marrow, marrow blasts \>5%, reduced by 50% or more for at least 4 weeks. HI: HI-E: Hb increase ≥1.5 g/dL in absence of RBC transfusions. HI-P: Absolute increase of platelet count from \<20 to \>20X10\^9/L by at least 100%,if more than 20x10\^9/L, by absolute increase of at least 30x10\^9/L in absence of platelet transfusions. HI-N: granulocyte increase ≥100%, by an absolute increase ≥0.5x10\^9/L for at least 8 weeks. Percentage of participants with CR, mCR, PR, and HI based on IWG 2003 MDS response criteria are reported. Response has been reported based on participants with MDS or CMML., Up to approximately 2.7 years|AML: Percentage of Participants With CR, CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Recovery (CRp), and CR Plus CRp Based on IWG 2003 AML Response Criteria, CR was defined as absolute neutrophil content (ANC) ≥1000/ microliter (μL), platelets ≥100,000/μL, independence from red blood cell (RBC) and platelet transfusions over the past week, no leukemic blasts and \<5% leukemic blasts. CRp was defined as CR criteria except platelets \<100,000/μL.and platelet transfusion over the past week. CRi was defined as CR criteria except ANC \<1000/μL or platelets \<100,000/μL. Percentage of participants with CR, CRi, CRp, and CR Plus CRp based on IWG 2003 AML response criteria are reported., Up to approximately 2.4 years|AML: Percentage of Participants With CR With Partial Hematologic Recovery (CRh) Based on IWG 2003 AML Response Criteria, CRh was defined as \<5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets \>50,000/μL and ANC \>500/μL), independence from RBC and platelet transfusions within 7 days of bone marrow evaluation, and peripheral blast ≤1%. Percentage of participants with CRh based on IWG 2003 AML response criteria are reported., Day 1 of Cycle 3 up to approximately 2.4 years (each cycle= 28 days)|AML: Time to First Response, Best Response and Complete Response Based on IWG 2003 AML Response Criteria, Time to first response was defined as time in months from the date of first treatment to the first date when any response is achieved. Time to best response was defined in months from the date of first treatment to the first date when a subject's best response, in the order of CR, CRi (or CRp or CRh), or PR, was achieved. Time to CR was defined in months from the date of first treatment to the first date when CR is achieved. CR:ANC ≥1000/ microliter (μL),platelets ≥100,000/μL,independence from RBC and platelet transfusions over the past week, no leukemic blasts, and \<5% leukemic blasts.CRp: CR criteria except ANC ≥1000/μL, platelets \< 100,000/μL.and platelet transfusion over the past week. CRi:CR criteria except ANC \<1000/μL or platelets \<100,000/μL.CRh: \<5% of blasts in the bone marrow,platelets \>50,000/μL and ANC \>500/μL, independence from RBC and platelet transfusions within 7 days and peripheral blast ≤1%. PR: CR criteria except decrease of ≥50% in leukemic blasts., Up to approximately 2.4 years|AML: Duration of Complete Response and Combined CR and CRh Based on IWG 2003 AML Response Criteria, Duration of CR was defined as the time interval from the first CR to time of relapse. Duration of combined CR and CRh was defined as the time interval from the first CR or CRh to time of relapse. Duration of CR and combined CR and CRh was presented using a Kaplan-Meier estimate., Up to approximately 2.4 years|MDS/CMML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI), Transfusion independence was defined as no transfusion for 56 consecutive days or more (84 and 112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI)., Up to approximately 2.7 years|AML: Percentage of Participants With Red Blood Cell (RBC) and Platelet Transfusion Independence (TI), Transfusion independence was defined as no transfusion for 56 consecutive days or more (112 days) after the first dose of study treatment while maintaining hemoglobin ≥8 grams/deciliter (g/dL) (RBC TI) or maintaining platelets ≥20×109/L (platelet TI)., Up to approximately 2.4 years|MDS/CMML: Leukemia-free Survival (LFS), LFS was defined as time from the date of randomization to the date when bone marrow or peripheral blood blasts reach ≥20%, or death from any cause. Participants who hadn't reached AML at the time of the analysis were censored at the date of the last follow-up. Leukemia-free survival was presented using a Kaplan-Meier estimate., From randomization up to approximately 2.7 years|MDS/CMML: Overall Survival (OS), OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate., From randomization up to approximately 2.7 years|AML: Overall Survival (OS), OS was defined as time from the date of randomization to the date of death from any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. Overall survival was presented using a Kaplan-Meier estimate., From randomization up to approximately 2.4 years|AML: Survival Rates at 6 Months, 1 Year, and 2 Years, One-year survival rate was defined as the survival rate at the end of the first year from the date of randomization. The survival rates at 6 months and at 2 years were calculated similarly., At Month 6, Year 1 and 2|AML: Event-free Survival (EFS), EFS was defined as time from the date of randomization to the date of treatment failure \[disease progression/relapse (due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse), discontinue treatment due to disease progression or treatment-related AE, or alternative anti-leukemia therapy except for HCT\] or death from any cause, whichever occurs first. Participants without documented treatment failure at the time of the analysis were censored at the date of the last follow-up. Event-free survival was presented using a Kaplan-Meier estimate., From randomization up to approximately 2.4 years|AML: Progression-free Survival (PFS), PFS was defined as time from the date of randomization to the date disease progression due to confirmed reappearance of leukemic blasts in peripheral blood or ≥5% leukemic blasts in bone marrow (including relapse) or death from any cause, whichever occurs first. Participants without documented disease progression/relapse or death at the time of the analysis were censored at the date of the last follow-up. Progression-free survival was presented using a Kaplan-Meier estimate., From randomization up to approximately 2.4 years",,"Astex Pharmaceuticals, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,227,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,ASTX727-02|2018-003395-12,2018-02-15,2021-09-10,2023-05-25,2017-10-11,2024-07-01,2024-08-27,"Pinnacle Research Group, Anniston, Alabama, 36207, United States|Mayo Clinic Arizona, Phoenix, Arizona, 85054, United States|Arizona Clinical Research Center, Tucson, Arizona, 85715, United States|Compassionate Cancer Care Research Group, Fountain Valley, California, 92708, United States|University of Southern California, Los Angeles, California, 90007, United States|Yale, New Haven, Connecticut, 06510, United States|Georgetown University, Washington, District of Columbia, 20007, United States|Boca Raton Clinical Research, Boca Raton, Florida, 33322, United States|Holy Cross Hospital, Fort Lauderdale, Florida, 33308, United States|Mount Sinai, Miami Beach, Florida, 33140, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Chicago, Chicago, Illinois, 60637, United States|Quincy Medical Group, Quincy, Illinois, 62301, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, 46237, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|Johns Hopkins, Baltimore, Maryland, 21287, United States|Regional Cancer Care Associates, Bethesda, Maryland, 20817, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, 48334, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, 49503, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Hackensack, Hackensack, New Jersey, 07601, United States|Montefiore, Bronx, New York, 10467, United States|Roswell Park, Buffalo, New York, 14263, United States|Monter Cancer Center, Lake Success, New York, 11042, United States|Weill Cornell Medicine, New York, New York, 10065, United States|Gabrail Cancer Center, Canton, Ohio, 44718, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oregon Health & Sciences University, Portland, Oregon, 20817, United States|West Penn Allegheny Cancer Institute, Pittsburgh, Pennsylvania, 15224, United States|University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Charleston Hematology Oncology Associates, Charleston, South Carolina, 29414, United States|Vanderbilt, Nashville, Tennessee, 37232, United States|Baylor Scott & White University Medical Center, Dallas, Texas, 75246, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390-9179, United States|Houston Methodist Cancer Center, Houston, Texas, 77030, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84124, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, 99336, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Uniklinikum Salzburg, Salzburg, 05020, Austria|General Hospital Hietzing, Vienna, 01130, Austria|Klinikum Wels-Grieskirchen, Wels, 4600, Austria|University of Alberta Hospital, Edmonton, Alberta, T6G 2B7, Canada|Queen Elizabeth II (QEII) Health Sciences Center, Halifax, Nova Scotia, B3H 2Y9, Canada|Juravinski Hospital & Cancer Center, Hamilton, Ontario, L8V 1C3, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, K1H8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Center - University Health Network, Toronto, Ontario, M5G 2M9, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Est-de-l'Ile-de-Montréal - Hôpital Maisonneuve Rosemont, Montréal, Quebec, H1T 2M4, Canada|FN Ostrava, Ostrava, Poruba, 708 00, Czechia|University Hospital Brno, Brno, 62500, Czechia|Fakultni Nemocnice Kralovske Vinohrady FNKV, Praha 10, Česká Republika, 10034, Czechia|Centre de lutte contre le Cancer Leon Berard, Lyon, Rhone, 69008, France|Hospital Emile Muller, Mulhouse, 68100, France|Universitaetsklinikum Freiburg, Freiburg im Breisgau, Baden, 79106, Germany|Philipps-Universität Marburg, Klinik für Innere medizin, Hämatologie, Onkologie und Immunologie, Marburg, Hesse, 35033, Germany|UNIVERSITTSKLINIKUM Schleswig-Holstein, Lubeck, Schleswig-Holstein, 23538, Germany|Staedtisches Klinikum Braunschweig, Braunschweig, 38114, Germany|Oberärztin für Innere Medizin, Hämato-/Onkologie und Palliativmedizin, Düsseldorf, 40479, Germany|University Hospital Halle, Halle, 06120, Germany|University of Leipzig, Leisnig, 04103, Germany|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Somogy Megyei KAposi Mor Oktato Korhaz, Kaposvár, 7400, Hungary|University of Pecs, 1st Department of Internal Medicine, Pecs, 7400, Hungary|University of Szeged, Szeged, 6725, Hungary|Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo, Alessandria, 15121, Italy|AOUC Azienda Ospedaliero-Universitaria Careggi, Firenze, 50134, Italy|Fondazione IRCCS C Granda OM Policlinico, Milan, 20122, Italy|Azienda Ospedaliero-Universitaria Maggiore della Carità Novara, Novara, 28100, Italy|Ospedale S. Eugenio, Rome, 00144, Italy|ULSS 8 Vicenza - Ospedale San Bortolo di Vicenza, Vicenza, 36100, Italy|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Hospital U. Marqués de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital San Pedro de Alcantara, Cáceres, 10003, Spain|Hospital Universitario Virgen de las Nieves, Granada, 18012, Spain|Hospital Duran i Reynals, L'Hospitalet De Llobregat, 08909, Spain|Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain|Clinica Universitaria Navarra, Madrid, 28027, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Clinica Universitaria Navarra, Pamplona, 31008, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitari I Politècnic La Fe, València, 46026, Spain|Oxford University Hopsitals NHS Trust, Oxford, Oxfordshire, OX3 7LE, United Kingdom|The Christie NHS Fundation Trust, Manchester, M20 4BX, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/64/NCT03306264/Prot_000.pdf|Statistical Analysis Plan: Statistical Analysis Plan (for MDS and CMML), https://cdn.clinicaltrials.gov/large-docs/64/NCT03306264/SAP_001.pdf|Statistical Analysis Plan: Statistical Analysis Plan (for AML), https://cdn.clinicaltrials.gov/large-docs/64/NCT03306264/SAP_002.pdf"
